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Abstract
Introduction: Adenocarcinoma of the ovary is an aggressive neoplasm which often metastasizes to the lung or
liver. Metastases rarely occur to the pancreas, but a tissue diagnosis is required to confirm this event. Although
most tumors of the pancreas are primary pancreatic neoplasms, metastatic lesions have been reported most
commonly as arising from renal cell carcinoma.
Case presentation: We report the case of a 51-year-old Caucasian woman with ovarian mucinous
adenocarcinoma with metastasis to the head of the pancreas that was originally misdiagnosed as a pancreatic
primary tumor.
Conclusion: Mucinous ovarian adenocarcinomas rarely metastasize to the pancreas. New pancreatic lesions should
be investigated through tissue biopsy and tumor markers, while keeping an open-minded differential diagnosis to
avoid a misdiagnosis or a delay in treatment.
Introduction
Although most malignant tumors of the pancreas are
primary pancreatic neoplasms, metastatic lesions have
been reported most commonly as arising from renal cell
carcinoma. Here we present a case of mucinous adeno-
c a r c i n o m ao ft h eo v a r yt h a tm e t a s t a s i z e dt ot h ep a n -
creas. The tumor was first diagnosed as a primary
pancreatic tumor. Ovarian adenocarcinoma can have
distant metastases, but these are most often to the liver
or lung. Metastasis to the pancreas is quite rare, and a
delay in its diagnosis may occur if the pancreatic tumor
is not identified as a metastatic disease.
Case presentation
A 51-year-old Caucasian woman complained of fatigue,
epigastric discomfort, a left neck mass, and a 10-pound
weight loss over the previous six months. Her physical
examination revealed supraclavicular lymphadenopathy.
A cervical lymph biopsy revealed moderately well-dif-
ferentiated adenocarcinoma, possibly of pancreatic ori-
gin. A metastatic workup including positron emission
tomography (PET) scan, computed tomography (CT),
bone scan, and breast and pelvic ultrasounds was done.
Significant cervical, retrosternal and retroperitoneal lym-
phadenopathy were seen. A 3.5 × 5-cm pancreatic head
mass which blended into the porta hepatis was also
noted. The mass encased the left gastric artery and
involved the portal vein margins. Multiple liver lesions
were also seen. Except for a fibroid uterus, her pelvic
CT and ultrasound were unremarkable.
A percutaneous liver biopsy of our patient revealed a
moderately well-differentiated adenocarcinoma consis-
tent with pancreatic origin. Her CA-19-9 level was
171.5.
Our patient was then entered into a trial for advanced
pancreatic adenocarcinoma using the tyrosine kinase
inhibitor Dasatinib. Her response to the trial, however,
was poor and a CT scan two months later showed no
reduction in her tumor burden. She was removed from * Correspondence: danielmchase@hotmail.com
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bine) and Tarceva (erlotinib).
Over the next seven months, our patient developed a
moderate response to chemotherapy. However, she
developed abdominal fullness and shortness of breath.
In just a four-month interval between scans, her CT
revealed a new 19 × 18 × 9 cm pelvic mass, ascites, and
a large right-sided pleural effusion. A CT-guided biopsy
revealed poorly differentiated adenocarcinoma. Meta-
static malignant cells were also found in her pleural
fluid.
Because our patient experienced significant discomfort
due to the effects of her pelvic mass, a palliative resec-
tion was performed. She had a transient response to
chemotherapy, but her disease continued to progress
with worsening ascites and pleural effusion.
Pathology revealed that her pelvic mass measured 19.0
× 18.0 × 9.0 cm. Sectioning revealed a multi-loculated
cystic mass involving her entire ovary (Figure 1). No
normal ovarian tissue was identified on gross examina-
tion. On histology the tumor was found to consist of a
complex formation of dilated cystic glands filled with
m u c i n .T h em u c i n o u sc y s t sw e r el i n e db yal a y e ro f
columnar mucinous cells with pale to clear cytoplasm
and a small, bland, basally situated oval nuclei. This
finding was consistent with a borderline mucinous
tumor. There were areas of invasion of her fallopian
tube and lymphatics (Figure 2). The tumor was also
found surrounding her residual ovarian stroma at the
periphery.
In view of the presence of metastatic adenocarcinoma
to the liver and a cervical lymph node (Figure 3), as well
as the pancreatic mass found on CT, we initially identi-
fied the primary tumor as pancreatic. Unfortunately, a
fine needle aspiration of the pancreas was not
diagnostic.
When her ovarian mass stained positive for CK7 but
negative for CK20 and estrogen receptor, we repeated
the stains on her liver and lymph node biospies, which
proved to be a match to the ovarian tumor.
T h eh i s t o l o g i ca n di m m u n o h i stochemical findings of
our patient’s ovarian mass are consistent with the results
of her lymph node and liver biopsies. We concluded
that the mass was most likely from the ovary and not
the pancreas, with the pancreatic mass representing
another metastasis of her ovarian adenocarcinoma.
Discussion
Mucinous ovarian adenocarcinomas are uncommon and
account for only 10% to 15% of reported cases of
Figure 1 Gross specimen with clearly defined cystic and
mucinous component (40× magnification).
Figure 2 Hematoxylin and eosin slide of the ovarian mucinous
carcinoma demonstrating lymphatic invasion (40×
magnification).
Figure 3 Hematoxylin and eosin slide of our patient’sl y m p h
node and metastasis (40× magnification).
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are considered borderline with low malignant potential
[2]. Tumors that metastasize are often poorly differen-
tiated and of the low-grade type [1].
Often characterized by multiseptated cystic lesions of
the adenexa, mucinous adenocarcinomas are filled with
a gelatinous material that may freely rupture into the
peritoneal cavity, thus causing a dissemination called
“pseudomyxoma peritoni” [2]. Pseudomyxoma peritoni
can arise from any other mucinous-type adenocarcino-
mas, including those of the appendix, breast, prostate,
and colon [1]. Ovarian neoplasms may also metastasize
to the lung or the liver [3] through lymphatic spread via
the deep inguinal nodal basin.
Carcinoma metastatic to the pancreas is uncommon and
arises by direct extension from retroperitoneal or mesen-
teric lymph nodes or from isolated metastases to the pan-
creatic parenchyma [4]. The most common primary origin
of solitary pancreatic metastases is renal cell carcinoma,
[5,6] but other sources include the lung and the colon [7].
Pancreatic metastasis from a gynecologic primary is rare
[4]. However, the incidence in advanced ovarian tumors
may be higher than had been previously considered. In
fact one autopsy study showed pancreatic metastases in
21% of patients with ovarian cancer [8]. The pancreatic
head remains the most common site of metastasis [5].
Due to the low incidence of pancreatic metastasis,
most masses of the pancreas are assumed to be primary
pancreatic neoplasms. However, a tissue biopsy is
required to truly differentiate between primary and sec-
ondary tumors [1]. A delay in diagnosis can occur when
this assumption is not verified by biopsy, as in the case
of a 72-year-old woman reported by Schumacher [9].
Her pancreatic mass was not recognized as ovarian until
10 months after its initial discovery. The lack of an ade-
nexal mass to initially raise suspicion of an ovarian pri-
mary tumor may also contribute to a delay in diagnosis,
as in our case.
Differentiating primary from secondary pancreatic
tumors is important in directing a patient’st h e r a p y ,
both in terms of chemotherapy and surgery. Whenever
possible, the resection of pancreatic metastasis can be a
reasonably safe palliative procedure [4]. Distal pancreatic
resection of metastatic ovarian cancers has been shown
to be beneficial, even if found incidentally during a
debulking procedure [10].
Conclusion
Although most lesions of the pancreas are primary pan-
c r e a t i cn e o p l a s m s ,at i s s u eb i o p s ys h o u l db eo b t a i n e d
whenever possible to differentiate between primary and
secondary tumors. Metastases of ovarian mucinous ade-
nocarcinomas to the pancreas are rare, but have been
reported in the literature. Confirmatory tissue biopsies,
tumor markers, and being mindful of the possibility of
metastatic disease can avoid misdiagnosis and delay in
treatment for newly discovered pancreatic masses.
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